Moleculin Biotech Inc (MBRX) posted a -29.30% change over the last five days signaling a new trend

A new trading day began on Friday, with Moleculin Biotech Inc (NASDAQ: MBRX) stock price down -10.99% from the previous day of trading, before settling in for the closing price of $0.64. MBRX’s price has ranged from $0.25 to $3.67 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 26.36%. Meanwhile, its annual earnings per share averaged 75.21%. With a float of $27.57 million, this company’s outstanding shares have now reached $30.21 million.

Let’s determine the extent of company efficiency that accounts for 17 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Moleculin Biotech Inc (MBRX) Breakdown of a Key Holders of the stock

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Moleculin Biotech Inc is 8.74%, while institutional ownership is 4.89%. The most recent insider transaction that took place on Jun 23 ’25, was worth 100,000. In this transaction Chief Financial Officer of this company bought 270,270 shares at a rate of $0.37, taking the stock ownership to the 287,587 shares. Before that another transaction happened on Jun 23 ’25, when Company’s CEO and President bought 675,675 for $0.37, making the entire transaction worth $250,000. This insider now owns 743,607 shares in total.

Moleculin Biotech Inc (MBRX) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 75.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.60% during the next five years compared to 26.36% growth over the previous five years of trading.

Moleculin Biotech Inc (NASDAQ: MBRX) Trading Performance Indicators

Here are Moleculin Biotech Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.35.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.80, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.36 in one year’s time.

Technical Analysis of Moleculin Biotech Inc (MBRX)

Looking closely at Moleculin Biotech Inc (NASDAQ: MBRX), its last 5-days average volume was 2.11 million, which is a drop from its year-to-date volume of 4.67 million. As of the previous 9 days, the stock’s Stochastic %D was 25.95%.

During the past 100 days, Moleculin Biotech Inc’s (MBRX) raw stochastic average was set at 29.63%, which indicates a significant increase from 25.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1289 in the past 14 days, which was higher than the 0.0907 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.6594, while its 200-day Moving Average is $1.4352. However, in the short run, Moleculin Biotech Inc’s stock first resistance to watch stands at $0.6115. Second resistance stands at $0.6561. The third major resistance level sits at $0.6818. If the price goes on to break the first support level at $0.5412, it is likely to go to the next support level at $0.5155. Now, if the price goes above the second support level, the third support stands at $0.4709.

Moleculin Biotech Inc (NASDAQ: MBRX) Key Stats

With a market capitalization of 17.13 million, the company has a total of 30,207K Shares Outstanding. Currently, annual sales are 0 K while annual income is -21,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -6,440 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.